Medicus Pharma (NASDAQ: MDCX) CEO awarded 325,000 options at $0.50 strike

Rhea-AI Filing Summary

Medicus Pharma Ltd. Chief Executive Officer Raza Bokhari received a grant of stock options for 325,000 Common Shares. The options have an exercise price of $0.50 per share and were awarded at no cost on the grant date.

The options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031 if not exercised. Following this grant, Bokhari holds stock options covering a total of 325,000 underlying Common Shares directly as reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bokhari Raza

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	325,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 325,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 325,000 options Exercise price: $0.50 per share Underlying shares: 325,000 Common Shares +4 more

7 metrics

Options granted 325,000 options Stock Option (right to buy) grant to CEO

Exercise price $0.50 per share Exercise/conversion price of granted options

Underlying shares 325,000 Common Shares Shares subject to the stock options

Total options after grant 325,000 options total_shares_following_transaction for derivative position

Grant date March 30, 2026 Transaction date for stock option award

Exercise start date March 26, 2027 Date options become exercisable

Expiration date March 27, 2031 Date stock options expire

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, underlying security, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 0.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Shares"

derivative transaction financial

"derivativeTransactionCount: 1"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bokhari Raza

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		325,000		03/26/2027	03/27/2031	Common Shares	325,000	$0	325,000	D

Explanation of Responses:

	/s/ Raza Bokhari	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Medicus Pharma (MDCX) CEO Raza Bokhari report on this Form 4?

Raza Bokhari reported receiving a grant of stock options for 325,000 underlying Common Shares. The options were awarded at no cost on the grant date and give him the right to buy shares at a fixed exercise price of $0.50 per share in the future.

How many Medicus Pharma (MDCX) options were granted to the CEO and at what price?

The CEO received stock options covering 325,000 underlying Common Shares with an exercise price of $0.50 per share. This means he can later purchase those shares at $0.50 each, regardless of the market price at the time of exercise.

When do Raza Bokhari’s Medicus Pharma (MDCX) stock options vest and expire?

The stock options become exercisable on March 26, 2027, giving the CEO the right to buy shares from that date. They expire on March 27, 2031, so any unexercised options after that date will lapse and no longer be usable.

Is this Medicus Pharma (MDCX) Form 4 an open-market buy or a compensation grant?

This Form 4 reflects a compensation-related grant, not an open-market purchase. The transaction code is “A” for a grant, award, or other acquisition, and the options were issued at no cost with an exercise price of $0.50 per share.

How many Medicus Pharma (MDCX) derivative securities does the CEO hold after this grant?

After this grant, the CEO is reported as holding stock options for 325,000 underlying Common Shares directly. This total_shares_following_transaction figure refers to the derivative position covered by the options disclosed in the filing.